Linked e-resources
Details
Table of Contents
Intro; Foreword; Disorders of Gut-Brain Interaction: A Coming of Age for the Clinician; Preface; Contents; Contributors; Chapter 1: The Gut-Brain Connection and Its Significance to Gastroenterologists; References; Chapter 2: How to Use Central Neuromodulators (CNs) to Help Manage Patients with Disorders of Gut-Brain Interaction (DGBI); When to Start Central Neuromodulators (CNs); The Monoamine Hypothesis; SSRIs, SNRIs, and TCAs; SSRIs; SNRIs; TCAs; Action of CNs on Various Receptors; Mirtazapine; Buspirone; Trazodone; Atypical Antipsychotics
On Choosing a Neuromodulator for a Specific SymptomFunctional Dyspepsia-EPS Type; Functional Dyspepsia-PDS Type; Nausea and Vomiting; Cyclic Vomiting Syndrome; Side Effects of Central Neuromodulators; Questions That Are Frequently Asked; Pitfalls in Management; References; Chapter 3: A Psychopharmacology Guide by Psychiatrists for Non-psychiatrists; Introduction; Principles of Psychopharmacology; Diagnosis and Symptom Assessment; Selecting a Psychopharmacology Treatment; Drug-Drug Interactions; Treatment Course; General Comments on Discontinuation; Antidepressants; Initiating; Monitoring
DiscontinuingFirst-Generation Antidepressants; Monoamine Oxidase Inhibitors; Tricyclic Antidepressants; Second-Generation Antidepressants; Selective Serotonin Reuptake Inhibitors; Serotonin and Norepinephrine Reuptake Inhibitors; Atypical Antidepressants; Serotonin Modulators; Benzodiazepines and Related Sedatives; Benzodiazepines; Adverse Effects; Discontinuation; Nonbenzodiazepine Hypnotics; Adverse Effects; Buspirone; Adverse Effects; Antipsychotics; Initiating; Monitoring; Discontinuing; First-Generation Antipsychotics (FGAs); Second-Generation Antipsychotics (SGAs)
Extrapyramidal Symptoms and Neuroleptic Malignant SyndromeMood Stabilizers; Initiating; Monitoring; Discontinuing; Lithium; Antiepileptics; Valproate; Carbamazepine; Lamotrigine; Psychopharmacology in the Medically Ill; Renal; Cardiovascular; Endocrine; References; Chapter 4: Discussion on the Use of Psychiatric Medications: Questions by W. Harley Sobin MD Answers by Thomas W. Heinrich MD; Chapter 5: Cognitive-Behavioral Therapy for Irritable Bowel Syndrome; Case 1: Shelly; Session 1; Session 2; Session 3; Session 4; Session 5; Session 6; Session 7; Session 8; Case 2: Tom; Session 1
Session 2Session 3; Session 4; Session 5; Session 6; Session 7; Session 8; Summary; References; Chapter 6: Exposure Therapy for Functional GI Disorders; The Nature of Anxiety; The Role of Negative Reinforcement; Exposure Therapy with Response Prevention Applied to Functional GI Disorders; Exposure Therapy for a Patient Disabled by Belly Pain; Beginning Treatment: Explain to Your Patient the Following Information; Defining Targets for Exposure; Making Exposure Therapy Successful; Exposure to Worry; Exposure to Uncertainty; Length of Treatment; Avoiding Being the Negative Reinforcer; Summary
On Choosing a Neuromodulator for a Specific SymptomFunctional Dyspepsia-EPS Type; Functional Dyspepsia-PDS Type; Nausea and Vomiting; Cyclic Vomiting Syndrome; Side Effects of Central Neuromodulators; Questions That Are Frequently Asked; Pitfalls in Management; References; Chapter 3: A Psychopharmacology Guide by Psychiatrists for Non-psychiatrists; Introduction; Principles of Psychopharmacology; Diagnosis and Symptom Assessment; Selecting a Psychopharmacology Treatment; Drug-Drug Interactions; Treatment Course; General Comments on Discontinuation; Antidepressants; Initiating; Monitoring
DiscontinuingFirst-Generation Antidepressants; Monoamine Oxidase Inhibitors; Tricyclic Antidepressants; Second-Generation Antidepressants; Selective Serotonin Reuptake Inhibitors; Serotonin and Norepinephrine Reuptake Inhibitors; Atypical Antidepressants; Serotonin Modulators; Benzodiazepines and Related Sedatives; Benzodiazepines; Adverse Effects; Discontinuation; Nonbenzodiazepine Hypnotics; Adverse Effects; Buspirone; Adverse Effects; Antipsychotics; Initiating; Monitoring; Discontinuing; First-Generation Antipsychotics (FGAs); Second-Generation Antipsychotics (SGAs)
Extrapyramidal Symptoms and Neuroleptic Malignant SyndromeMood Stabilizers; Initiating; Monitoring; Discontinuing; Lithium; Antiepileptics; Valproate; Carbamazepine; Lamotrigine; Psychopharmacology in the Medically Ill; Renal; Cardiovascular; Endocrine; References; Chapter 4: Discussion on the Use of Psychiatric Medications: Questions by W. Harley Sobin MD Answers by Thomas W. Heinrich MD; Chapter 5: Cognitive-Behavioral Therapy for Irritable Bowel Syndrome; Case 1: Shelly; Session 1; Session 2; Session 3; Session 4; Session 5; Session 6; Session 7; Session 8; Case 2: Tom; Session 1
Session 2Session 3; Session 4; Session 5; Session 6; Session 7; Session 8; Summary; References; Chapter 6: Exposure Therapy for Functional GI Disorders; The Nature of Anxiety; The Role of Negative Reinforcement; Exposure Therapy with Response Prevention Applied to Functional GI Disorders; Exposure Therapy for a Patient Disabled by Belly Pain; Beginning Treatment: Explain to Your Patient the Following Information; Defining Targets for Exposure; Making Exposure Therapy Successful; Exposure to Worry; Exposure to Uncertainty; Length of Treatment; Avoiding Being the Negative Reinforcer; Summary